

Lipidor presents Nomination Committee

STOCKHOLM, Sweden, 3rd December 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today presents its Nomination Committee, which shall have four members, in accordance with the applicable instructions resolved by the Annual General Meeting 2020.

The three largest shareholders who are registered with Euroclear Sweden AB on the last of September before the meeting are to be contacted by the company's Chairman of the Board. These three largest shareholders have the right to appoint a member of the Nomination Committee. In addition, the Chairman of the Board shall be a member of the Nomination Committee.

As of 30th September 2024, the three largest shareholders were Aurena Laboratories AB, Life Science Investment Fund 1 Aps, and Denis Kristoffer Pedersen. All have agreed to be part of the Nomination Committee.

The Nomination Committee consists of the following members:

- Magnus Hedman, appointed by Aurena Laboratories AB
- Jan Paulsen, appointed by Life Science Investment Fund, also chairman of the Nomination Committee
- Joel Hagman, appointed by Denis Kristoffer Pedersen
- Fredrik Sjövall, Chairman of the Board

No later than six weeks before the Annual General Meeting, the Nomination Committee shall submit proposals regarding: Chairman of the AGM; Chairman, other Board members and any Deputy Board members; fees to the Chairman and other Board members; election of auditor and fees to the auditor; and, where applicable, changes in these instructions and rules of procedure for the nomination committee.

The nomination committee's proposals will be presented in the notice convening the Annual General Meeting 2025 and on the company's website, www.lipidor.se. Shareholders who wish to submit proposals to Lipidor's nomination committee for the 2025 Annual General Meeting may do so by e-mail to: info@lipidor.se (title e-mail with the "Nomination Committee") or by letter to the address: Lipidor AB, FAO: Nomination Committee, c/o Ekonomistubben, Box 55931, 102 16 Stockholm.

“On behalf of the Nomination Committee, I would like to encourage our shareholders to take the opportunity to submit proposals to the Nomination Committee,” says Chairman of the Nomination Committee, Jan Poulsen.

Lipidor's Annual General Meeting 2025 will be held on Tuesday 3rd June 2025 in Stockholm. A request to have a matter dealt with at the meeting must be received no later than 15th April 2025 in order to be included in the notice.

Publication

The information was provided for publication by Lipidor's CEO on 3rd December 2024 at 8.00 am (CET).

For more information, please contact:

Ola Holmlund, CEO, Lipidor AB (publ)

Telephone: +46 (0) 72 50 70 369

Email: ola.holmlund@lipidor.se

The company's Certified Adviser is Carnegie Investment Bank AB (publ).

About Lipidor AB

Lipidor AB (Nasdaq First North Growth Market: LIPI) (www.lipidor.se) is a pharmaceutical development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The company can develop topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances. Lipidor's priority project is AKP02G2, which focusses on psoriasis.

Attachments

[Lipidor presents Nomination Committee](#)